GA
KRTX

General Atlantic’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

General Atlantic’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-986,710
Closed -$312M – 25
2023
Q4 		$312M Hold
986,710
– – 4.48% 8
2023
Q3 		$167M Buy
986,710
+259,752
+36% +$48.8M 2.58% 10
2023
Q2 		$158M Buy
726,958
+10,800
+2% +$2.31M 2.48% 10
2023
Q1 		$130M Hold
716,158
– – 1.51% 13
2022
Q4 		$141M Buy
716,158
+301,158
+73% +$64.6M 1.86% 12
2022
Q3 		$93.3M Buy
+415,000
New +$84M 1.1% 14

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

General Atlantic's KRTX Position: Q1 2024 in Review

General Atlantic sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 986,710 shares — an estimated $312M sold.

General Atlantic first reported a position in KRTX in Q3 2022 and held it in 6 quarters. The position peaked at $312M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • General Atlantic reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • General Atlantic sold 986,710 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $312M.
  • General Atlantic first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 6 quarters.
  • General Atlantic's Karuna Therapeutics, Inc. Common Stock position peaked at $312M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on General Atlantic's 13F filing for Q1 2024, filed 15 May 2024.